Author: BusinessWire

Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 20211

Biologics License Application accepted by the FDA under Priority Review

Marketing Authorization Application submitted in Europe with potential approval in …

– AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 –
BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outsid…

Proceeds will Support Continued Advancement of Founding Vision
to Reshape Drug Discovery and Development of Transformative Medicines

Paul McCracken, Senior Portfolio Manager, Thematic Investing, at CPP Investments, to Join Board of Directors
SOUTH SA…

– Lead clinical program, an EGFR / TGFβ-trap bifunctional antibody, rapidly enrolling a Phase 1/2 study in leading research hospitals in U.S. and Canada

– $40 million in seed financing from global pharmaceutical company Biocon, Ltd.

– International …

Conference Call Scheduled for March 15 at 8 a.m. Eastern Daylight Time
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company will host a virtual investor ev…

–  Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir –

–  Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in H…

Veteran biopharma CFO brings over 20 years of experience leading finance functions at publicly traded pharmaceutical companies
UTRECHT, The Netherlands & PHILADELPHIA–(BUSINESS WIRE)–LAVA Therapeutics B.V. (“LAVA”, or the “Company”), a biotechnology…

REYKJAVIK, Iceland & LUXEMBOURG–(BUSINESS WIRE)–Biopharmaceutical company Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million. The first round which was completed in October 2020, amounted t…

Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours

Trial concluded that treatment accele…

90% of evaluable patients (27/30) alive and free of major functional disabilities (MFDs) at two years follow-up in Phase 2/3 Starbeam study (ALD-102)

Patients in long-term follow-up study (LTF-304) continue to remain alive and MFD-free through up to…